CoChat
Sign Up
Cited by 234Mesenchymal stem cell researchPeriodontal Regeneration and TreatmentsOsteoarthritis Treatment and Mechanisms

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique

J. Centeno, Christopher, R. Schultz, John, Cheever, Michelle, Freeman, Michael, Faulkner, Stephen, Robinson, Brent, Hanson, Ronald·2011·Current Stem Cell Research & Therapy
DOI 10.2174/157488811797904371
Open this paper in CoChat — free account

Abstract

UNLABELLED: Mesenchymal stem cells (MSCs) hold great promise as therapeutic agents in regenerative medicine. Numerous animal studies have documented the multipotency of MSCs, showing their capabilities for differentiating into orthopedic tissues such as muscle, bone, cartilage, and tendon. However, the safety of culture expanded MSC's for human use has only just begun to be reported. METHODS: Between 2006 and 2010, two groups of patients were treated for various orthopedic conditions with culture-expanded, autologous, bone marrow-derived MSCs (group 1: n=50; group 2: n=290-one patient in both groups). Cells were cultured in monolayer culture flasks using an autologous platelet lysate technique and re-injected into peripheral joints or into intervertebral discs with use of c-arm fluoroscopy. While both groups had prospective surveillance for complications, Group 1 additionally underwent 3.0T MRI tracking of the re-implant sites. RESULTS: The mean age of patients treated was 53 +/- 13.85 years; 214 were males and 125 females with mean follow-up time from any procedure being 435 days +/- 261 days. Number of contacts initiated based on time from first procedure was 482 at 3 months, 433 at 6 months, 316 contacts at 12 months, 110 contacts at 24 months, and 22 contacts at 36 months. For Group 1, 50 patients underwent 210 MRI surveillance procedures at 3 months, 6 months, 1, 2, and 3 years which failed to demonstrate any tumor formation at the re-implant sites. Formal disease surveillance for adverse events based on HHS criteria documented significantly less morbidity than is commonly reported for more invasive surgical procedures, all of which were either self-limited or were remedied with therapeutic measures. Two patients were diagnosed with cancer out of 339 patients treated since study inception; however, this was almost certainly unrelated to the MSC therapy and the neoplasm rate in similar to that seen in the U.S. Caucasian population. Knee outcome data was collected on a subset of patients. Here, > 75% improvement was reported in 41.4% while decreasing the improvement threshold to > 50% improvement, 63.2% reported an improvement. At an average reporting time of 11.3 months from first procedure average reported relief in the knee sample equaled 53.1% (n=133 reporting). CONCLUSIONS: Using both intensive high field MRI tracking and complications surveillance in 339 patients, no neoplastic complications were detected at any stem cell re-implantation site. These findings are consistent with our prior publication and other published reports that also show no evidence of malignant transformation in vivo, following implantation of MSCs for orthopedic use.

Overview

Integrity signals

Registry

Crossref · 10.2174/157488811797904371

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
J. Centeno, C., R. Schultz, J., Cheever, M., Freeman, M., Faulkner, S., Robinson, B., & Hanson, R.
ORCID
Freeman, Michael
Venue
Current Stem Cell Research & Therapy
Publisher
Bentham Science Publishers Ltd.
Published
2011-12-01
Volume
6
Issue
4
Pages
368-378
ISSN
1574-888X (ISSN-L)
DOI
10.2174/157488811797904371
OpenAlex
W2168562733
Cited by
234
References
43
Citations by year
2026: 2 · 2025: 3 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 9 · 2019: 21 · 2018: 18 · 2017: 24 · 2016: 22 · 2015: 28 · 2014: 25 · 2013: 28 · 2012: 18
FWCI
13.22
Type
journal article
Language
en
Open access
closed
Locations
  • Current Stem Cell Research & Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
Keywords
mesenchymal stem cells, bone marrow-derived stem cells, cell therapy safety, adverse events, tumor formation, orthopedic conditions, regenerative medicine, complication surveillance, fluoroscopy-guided injection
MeSH terms
Adult, Aged, Blood Platelets, Bone Marrow Cells, Drug Evaluation, Female, Fluoroscopy, Follow-Up Studies, Humans, Knee Joint, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies, Surveys and Questionnaires, Replantation, Transplantation, Autologous, Treatment Outcome, Cell Culture Techniques, Orthopedic Procedures, Regenerative Medicine, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review